Ignite Creation Date:
2024-05-06 @ 2:32 AM
Last Modification Date:
2024-10-26 @ 11:19 AM
Study NCT ID:
NCT02065856
Status:
COMPLETED
Last Update Posted:
2015-01-14
First Post:
2014-01-20
Brief Title:
An Open Trial to Assess the Tolerability of AVANZ Salsola Immunotherapy
Sponsor:
ALK-Abelló AS
Organization:
ALK-Abelló AS
Study Overview
Official Title:
An Open Trial to Assess the Tolerability of AVANZ Salsola Immunotherapy
Status:
COMPLETED
Status Verified Date:
2015-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AV-X-02
Brief Summary:
This trial is an open national multi-centre trial The trial will be initiated in December 2013 and subjects will receive treatment for 6 weeks
Safety monitoring will be performed in an ongoing basis through a Clinical Safety Group with immediate access to Adverse Events registered in the clinical database The composition procedures and deliverables of the Clinical Safety Group will be detailed in a Safety Agreement prior to trial start
Safety monitoring will be performed in an ongoing basis through a Clinical Safety Group with immediate access to Adverse Events registered in the clinical database The composition procedures and deliverables of the Clinical Safety Group will be detailed in a Safety Agreement prior to trial start
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2013-001728-20 | EUDRACT_NUMBER | None | None |